An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
NCT ID: NCT01118325
Last Updated: 2014-07-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
146 participants
INTERVENTIONAL
2010-04-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
NCT01294462
Comparing Ticagrelor Versus Clopidogrel on Microcirculation
NCT02618733
Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes
NCT02319941
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
NCT00642811
Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.
NCT02071212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD6140 45 mg bd
ticagrelor
Drug oral treatment
AZD6140 90 mg bd
ticagrelor
Drug oral treatment
Clopidogrel 75 mg od
clopidogrel
Drug oral treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ticagrelor
Drug oral treatment
clopidogrel
Drug oral treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previous documented acute coronary syndrome (ACS), more than 3 months prior to randomisation
* Treatment with ASA
Exclusion Criteria
* Known concurrent disease of stroke or TIA with atrial fibrillation
* Persons who are being treated with blood clotting agents that cannot be stopped
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan C. Fox, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Miyaodai, Fukuoka, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Toride-shi, Ibaraki, Japan
Research Site
Kawasaki-shi, Kanagawa, Japan
Research Site
Kyoto, Kyoto, Japan
Research Site
Ōita, Oita Prefecture, Japan
Research Site
Naha, Okinawa, Japan
Research Site
Osaka, Osaka, Japan
Research Site
Kusatsu-shi, Shiga, Japan
Research Site
Komatsushima-shi, Tokushima, Japan
Research Site
Shinagawa-ku, Tokyo, Japan
Research Site
Davao City, , Philippines
Research Site
Quezon City, , Philippines
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014 Oct;29(4):324-33. doi: 10.1007/s12928-014-0277-1. Epub 2014 Jun 17.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
CSR-D5130C00065.pdf
D5130C00065\_CSP\_redacted\_17\_Oct\_2013
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5130C00065
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.